Organogenesis Buyback Of Apligraf Rights Could Create Acquisition Target
This article was originally published in The Gray Sheet
Executive Summary
Organogenesis is seeking to raise $20-40 mil. to repurchase worldwide marketing rights to its Apligraf bi-layered skin substitute from Novartis and avoid a bankruptcy filing by year-end
You may also be interested in...
Organogenesis
Shipments of Apligraf bi-layered, living skin substitute to Novartis Pharma AG will be suspended until the two firms can reach an "equitable resolution" over how to restructure their supply arrangement. The companies have been in discussions since July over amending the relationship; however, no agreement has been reached and talks are ongoing (1"The Gray Sheet" July 15, 2002, p. 15). As a result of the halted shipments, Organogenesis will place 110 of its employees on furlough for up to two weeks until a resolution is met...
Organogenesis
Shipments of Apligraf bi-layered, living skin substitute to Novartis Pharma AG will be suspended until the two firms can reach an "equitable resolution" over how to restructure their supply arrangement. The companies have been in discussions since July over amending the relationship; however, no agreement has been reached and talks are ongoing (1"The Gray Sheet" July 15, 2002, p. 15). As a result of the halted shipments, Organogenesis will place 110 of its employees on furlough for up to two weeks until a resolution is met...
Organogenesis Apligraf U.S. Shipments By Novartis To Begin In June
Organogenesis Apligraf skin graft shipments are scheduled to begin in June following FDA approval May 22 for treatment of venous ulcers.